Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
| The following article is part of conference coverage from the 2018 American Psychiatric Association (APA) Annual Meeting in New York, New York. Psychiatry Advisor’s staff will be reporting breaking news associated with research conducted by leading experts in psychiatry. Check back for the latest news from APA 2018. |
In pediatric patients with attention-deficit/hyperactivity disorder (ADHD), treatment with dasotraline 4 mg/day was effective in treating a range of ADHD-related symptoms and behaviors, according to research presented at the 2018 American Psychiatric Association (APA) Annual Meeting, held May 5 to 9, 2018, in New York City.
A post hoc analysis of a randomized, double-blind, placebo-controlled study assessed changes in ADHD symptoms and behaviors in pediatric patients (aged 6-12 years) who were diagnosed with ADHD and randomly assigned to receive either dasotraline (2 mg/day or 4 mg/day) or placebo.
ADHD symptoms and behaviors were assessed using 18 items from the ADHD Rating Scale Version IV-Home Version (ADHD RS-IV HV) at week 6.
At the week 6 follow-up, treatment with dasotraline was associated with a statistically significant improvement in ADHD RS-IV HV scores for the 4 mg/day dose (−17.5 vs −11.4; P <.0001), but not for the 2 mg/day dose (−11.8 vs −11.4). Of 18 symptoms and behaviors, 14 were significantly improved by week 6 on the 4 mg/day dose.
In children with ADHD, a 6-week treatment of dasotraline 4 mg/day, but not treatment with 2 mg/day, led to significant improvements in ADHD-associated symptoms and behaviors.
For more coverage of APA 2018, click here.
Reference
Goldman R, Pikalov A, Deng L, Loebel AD. Improvement in ADHD-related symptoms and behaviors in children with ADHD treated with dasotraline: results of a post hoc ADHD-RS-IV item analysis. Presented at: 2018 American Psychiatric Association (APA) Annual Meeting; New York, NY; May 5-9. Poster 194.
